+441518081136Innovative Cancer care solutions: Insights from Skolkovo Foundation
12th World Cancer Congress
July 23-25, 2018 | Moscow, Russia
Veronika Aksenova
Skolkovo Foundation, Russia
Scientific Tracks Abstracts : J Med Oncl Ther
Abstract:
I will represent activities of Skolkovo Foundation that aims at building innovative eco-system to support entrepreneurial infrastructure, including biomedical technologies development on the Russian market. As a Project Manager in Oncology I will talk about success stories of start-up companies in our portfolio that develop innovative healthcare solutions to treat cancer. One of them is OncoTartis, Inc. (Buffalo, NY/ Moscow, Russia) that develops a novel category of anti-cancer drugs directed against tissue-specific targets for a subset of cancers (breast, prostate, ovarian, melanoma and hematological malignancies). Its leading product OT-82 is a nicotinamide phosphoribosyltransferase (NAMPT) inhibitor being developed to treat Acute Myeloid Leukemia (AML). Investigational New Drug application (IND) will be submitted to FDA in the forth quarter of 2017. Oncotartis got Skolkovo grant in 2016, became Skolkovo Start-up Village winner in 2017 and recently got $6M investments to support Phase 1 Clinical trials. Another success story is represented by the example of Unim LLC, resident of Skolkovo development zone, that designed Digital pathology© software enabling to distantly analyze wide range of histological slides and DICOM files, including MRT, CT scan and PET-CT in patients with ontological diagnosis. Digital pathology© cloud platform allows to minimize the risk of wrong diagnosis, reduce the decision-taking time, offers a worldwide histological slides database for research and publication purposes as well remote expert council. The company plans to accumulate significant amount of Medical Big Data that allows testing deep machinelearning techniques and artificial neuronal network algorithms.
Biography:
Veronika Aksenova was born in Moscow at 1990, she graduated from Cell Biology Department at Lomonosov Moscow State University. Later she did several internships on molecular oncology in the leading international research labs in Lausanne University, Karolinska Insitutet in Stockholm and German Cancer Research Center (DKFZ) in Heidelberg, Germany. Following her graduation, She started work as an R&D engineer for” Pharmapark LLC”, Russian biotech company and participated in the development of anti-cancer generic drugs for domestic market. Recently she got PhD degree in Developmental Biology from Aix-Marseille University, France. Currently she is working for an non-profit Skolkovo Foundation, Russia as a project manager supervising start-up companies that offer innovative healthcare solutions in oncology
E-mail: veronika.aksenova.msu@gmail.com
PDF HTML